Publications of Roland T. Ullrich
All genres
Journal Article (32)
2020
Journal Article
42, 101085 (2020)
Hepatic FTO is dispensable for the regulation of metabolism but counteracts HCC development in vivo. Molecular Metabolism 2015
Journal Article
16, 7 (2015)
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology
Journal Article
6 (36), pp. 38458 - 38468 (2015)
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget 2014
Journal Article
74 (10), pp. 2816 - 2824 (2014)
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. Cancer Research
Journal Article
4 (4), pp. 415 - 422 (2014)
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discovery
Journal Article
4 (2), pp. 246 - 257 (2014)
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discovery
Journal Article
134 (12), pp. 2829 - 2840 (2014)
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. International Journal of Cancer 2013
Journal Article
123 (4), pp. 1732 - 1740 (2013)
Tumor vegf:vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Journal of Clinical Investigation 2012
Journal Article
4 (141), 141ra91 (2012)
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science Translational Medicine
Journal Article
39 (7), pp. 1117 - 1127 (2012)
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging
Journal Article
109 (42), pp. 17034 - 17039 (2012)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America
Journal Article
137 (42), pp. 2179 - 2180 (2012)
Personalisierte Therapie von Lungenkrebs. Deutsche Medizinische Wochenschrift 2011
Journal Article
10 (6), pp. 453 - 459 (2011)
Imaging of non-or very subtle contrast-enhancing malignant gliomas with [ 11C]-methionine positron emission tomography. Molecular Imaging
Journal Article
52 (12), pp. 1 - 7 (2011)
Quantitative analysis of response to treatment with Erlotinib in advanced non–small cell lung cancer using 18F-FDG and 39-deoxy-39-18F-fluorothymidine PET. Journal of Nuclear Medicine
Journal Article
6 (5), p. e19592 - e19592 (2011)
In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice. PLoS ONE
Journal Article
84 (Spec. Iss. 2), pp. S179 - S195 (2011)
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. British Journal of Radiology
Journal Article
29 (13), pp. 1701 - 1708 (2011)
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F] fluorodeoxyglucose and [ 18F] fluorothymidine positron emission tomography. Journal of Clinical Oncology 2010
Journal Article
143 (2), pp. 201 - 211 (2010)
Cytohesins are cytoplasmic ErbB receptor activators. Cell
Journal Article
9 (1), pp. 40 - 46 (2010)
Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Molecular Imaging
Journal Article
37 (1), pp. 84 - 92 (2010)
Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. European Journal of Nuclear Medicine and Molecular Imaging